Pharmaceutical compositions comprising DGLA and use of same
The present disclosure provides orally deliverable pharmaceutical compositions comprising DGLA and to methods of using same to treat a variety of conditions and disorders.
1. A method of treating atopic dermatitis in a subject in need thereof, the method comprising orally administering to the subject at least 200 mg per day of a pharmaceutical composition comprising dihomo gamma linolenic acid, eicosatetraenoic acid, eicosatrienoic acid, oleic acid, linoleic acid and eicosadienoic acid encapsulated in a capsule shell wherein the composition comprises at least about 80% dihomo gamma linolenic acid by weight of total fatty acids.
2. The method of claim 1 wherein about 200 mg to about 4 g of the pharmaceutical composition is administered to the subject per day.
3. The method of claim 2 wherein the composition is present in one or more capsules each comprising a capsule shell.
4. The method of claim 3 wherein the capsule shell comprises gelatin and glycerol.
5. The method of claim 3 wherein about 200 mg to about 1 g of the composition is encapsulated in each of said one or more capsules.
6. The method of claim 3 wherein about 500 mg to about 1 g of the composition is encapsulated in each of said one or more capsules.
7. The method of claim 3 wherein the capsule shell comprises lime bone gelatin and one or more of: glycerol, purified water, titanium dioxide, medium chain triglycerides and/or lecithin.
8. The method of claim 1 wherein the composition comprises not more than 5%, by weight of total fatty acids, of any individual fatty acid other than dihomo gamma linolenic acid.
9. The method of claim 6 wherein the composition comprises not more than 5%, by weight of total fatty acids, of any individual fatty acid other than dihomo gamma linolenic acid.
10. A method of treating atopic dermatitis in a subject in need thereof, the method comprising orally administering to the subject about 500 mg to about 2 g per day of a pharmaceutical composition comprising dihomo gamma linolenic acid, eicosatetraenoic acid, eicosatrienoic acid, oleic acid, linoleic acid and eicosadienoic acid encapsulated in a capsule shell, wherein the composition comprises at least about 80% dihomo gamma linolenic acid by weight of total fatty acids and not more than 5%, by weight of total fatty acids, of any individual fatty acid other than dihomo gamma linolenic acid.